Largest biotech by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech ranked by net assets, at NOK 220.2B, ahead of BioNTech (NOK 206.8B) and Biogen (NOK 177B). Figures as of 18 Nov 2026, 14:31 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesNOK 220.2B
- Median
- NOK 19.5B
- Combined market value
- NOK 8.15T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | NOK 220.2B | NOK 2.02T | NOK 1,627.54 | 1.43% down | 33% up | ||
| 2 | BioNTechBNTX · Health Care | NOK 206.8B | NOK 202.7B | NOK 817.70 | 0.64% down | 16% down | ||
| 3 | BiogenBIIB · Health Care | NOK 177B | NOK 354.1B | NOK 2,395.29 | 1.51% down | 49% up | ||
| 4 | AmgenAMGN · Health Care | NOK 84B | NOK 2.37T | NOK 4,376.60 | 1.45% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | NOK 83.9B | NOK 804.3B | NOK 1,987.90 | 0.88% down | 755% up | ||
| 6 | argenxARGX · Health Care | NOK 71B | NOK 577.7B | NOK 9,186.78 | 0.02% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | NOK 36.6B | NOK 99.6B | NOK 482.11 | 0.07% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | NOK 31.5B | NOK 162B | NOK 1,600.10 | 0.55% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | NOK 26B | NOK 91B | NOK 574.87 | 0.20% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | NOK 21B | NOK 161.6B | NOK 662.15 | 0.32% down | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | NOK 20.4B | NOK 110.8B | NOK 705.21 | 0.12% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | NOK 20.4B | NOK 103.5B | NOK 1,619.49 | 2.97% up | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | NOK 18.6B | NOK 38.1B | NOK 392.51 | 0.81% up | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | NOK 15.8B | NOK 339.8B | NOK 1,571.15 | 0.41% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | NOK 15.3B | NOK 99.8B | NOK 1,168.65 | 0.83% down | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | NOK 11.8B | NOK 85.5B | NOK 2,885.99 | 0.32% down | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | NOK 8.3B | NOK 67B | NOK 323.70 | 0.51% up | 43% up | ||
| 18 | CG OncologyCGON · Health Care | NOK 7.3B | NOK 69.3B | NOK 775.80 | 1.34% up | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | NOK 4.6B | NOK 73.1B | NOK 1,072.36 | 1.27% down | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | NOK 2.4B | NOK 52.4B | NOK 429.41 | 1.77% down | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | NOK 2.1B | NOK 44.8B | NOK 276.67 | 0.14% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | NOK 1.5B | NOK 61.2B | NOK 935.91 | 0.30% down | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | NOK 473.4M | NOK 105.6B | NOK 925.97 | 0.51% down | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -NOK 4.9B | NOK 64.2B | NOK 60.32 | 0.64% down | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6975 NOK).
Questions and answers
Which biotech rank first by net assets?
Gilead Sciences (NOK 220.2B), BioNTech (NOK 206.8B) and Biogen (NOK 177B) are the top three of the 24 biotech ranked by net assets as of 18 Nov 2026, 14:31 UTC.
How many biotech are in this ranking?
24 are ranked by net assets.
What are these biotech worth together?
The 24 biotech ranked by net assets have a combined market value of NOK 8.15T as of 18 Nov 2026, 14:31 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.